Published in Ann Oncol on April 07, 2006
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res (2010) 3.35
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys (2011) 1.74
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist (2010) 1.52
Whole-brain radiation therapy in breast cancer patients with brain metastases. Nat Rev Clin Oncol (2010) 1.50
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol (2013) 1.45
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res (2009) 1.36
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer (2009) 1.30
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res (2012) 1.26
Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol (2012) 1.22
Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol (2014) 1.21
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res (2010) 1.16
Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis (2008) 1.14
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One (2012) 1.12
Brain metastases free survival differs between breast cancer subtypes. Br J Cancer (2012) 1.11
Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions. BMC Med Res Methodol (2013) 1.11
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev (2012) 1.06
Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol (2009) 1.03
Leptomeningeal metastases in breast cancer. Am J Cancer Res (2013) 1.00
Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study. Oncologist (2014) 1.00
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer (2012) 1.00
Breast cancer brain metastases: the last frontier. Exp Hematol Oncol (2015) 0.99
Epidemiology and prognosis of brain metastases. Surg Neurol Int (2013) 0.99
Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer (2010) 0.98
Leptomeningeal metastasis in breast cancer - a systematic review. Oncotarget (2016) 0.97
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer (2011) 0.96
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res (2012) 0.95
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer (2014) 0.94
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int J Clin Oncol (2012) 0.94
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
A subset of breast cancer predisposes to brain metastasis. Med Mol Morphol (2011) 0.91
Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med (2015) 0.90
Targeted therapy in her2-positive metastatic breast cancer: a review of the literature. Curr Oncol (2015) 0.89
Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience (2013) 0.89
Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis (2013) 0.88
In Vivo Magnetic Resonance Imaging for Investigating the Development and Distribution of Experimental Brain Metastases due to Breast Cancer. Transl Oncol (2012) 0.88
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer (2012) 0.87
Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am (2010) 0.87
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol (2015) 0.87
Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer (2015) 0.86
Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients. BMC Cancer (2015) 0.86
Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. Springerplus (2013) 0.85
Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol (2014) 0.84
Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells. Oncotarget (2015) 0.83
Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer (2011) 0.83
Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion. Clin Exp Metastasis (2012) 0.82
Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat (2012) 0.82
Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget (2015) 0.82
High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers. Transl Oncol (2014) 0.80
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol (2015) 0.80
Ductal barriers in mammary epithelium. Tissue Barriers (2013) 0.80
The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review. Contemp Oncol (Pozn) (2013) 0.79
Clinical outcome in gamma knife radiosurgery for metastatic brain tumors from the primary breast cancer : prognostic factors in local treatment failure and survival. J Korean Neurosurg Soc (2013) 0.79
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol (2010) 0.79
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol (2008) 0.79
Trends in survival after surgery for breast cancer metastatic to the brain and spinal column in medicare patients: a population-based analysis. Neurosurgery (2011) 0.77
Chemotherapy as primary treatment for brain metastases from breast cancer: analysis of 115 one-year survivors. J Cancer Res Clin Oncol (2012) 0.77
Breast carcinoma subtypes show different patterns of metastatic behavior. Virchows Arch (2017) 0.77
CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. J Cancer Res Clin Oncol (2012) 0.76
Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer. J Cancer Res Clin Oncol (2013) 0.76
Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis. Breast Care (Basel) (2015) 0.75
Risk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases. Prz Menopauzalny (2015) 0.75
Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer. J Cancer Epidemiol (2012) 0.75
Radiotherapy of brain metastases from breast cancer: Treatment results and prognostic factors. Oncol Lett (2016) 0.75
Methods and results of local treatment of brain metastases in patients with breast cancer. Contemp Oncol (Pozn) (2017) 0.75
Neuroborreliosis Mimicking Leptomeningeal Carcinomatosis in a Patient With Breast Cancer: A Case Report. J Investig Med High Impact Case Rep (2014) 0.75
Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? EPMA J (2017) 0.75
Clinical outcome of brain metastases differs significantly among breast cancer subtypes. Oncol Lett (2017) 0.75
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. Front Oncol (2017) 0.75
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat (2017) 0.75
Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran. Asian J Neurosurg (2017) 0.75
A Case of Breast Cancer Brain Metastasis with a 16-Year Time Interval without Evidence of Cancer Recurrence. J Breast Cancer (2017) 0.75
A small cosmid for efficient cloning of large DNA fragments. Gene (1980) 22.61
Cosmids: a type of plasmid gene-cloning vector that is packageable in vitro in bacteriophage lambda heads. Proc Natl Acad Sci U S A (1978) 16.33
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Comparison of two methods of screening for genital chlamydial infection in women attending in general practice: cross sectional survey. BMJ (1997) 5.29
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22
Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst (1997) 4.60
School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep (1994) 4.50
Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial. Ann Oncol (1992) 4.41
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol (1996) 4.02
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Plasmids useable as gene-cloning vectors in an in vitro packaging by coliphage lambda: "cosmids". Gene (1978) 3.66
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) (1986) 3.52
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst (2002) 3.20
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Activation of a transposable element in the germ line but not the soma of Caenorhabditis elegans. Nature (1987) 3.00
Gonadotrophin stimulation test ovarian function. Br Med J (1968) 2.99
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Organization and function of an accident flying squad. Br Med J (1966) 2.88
Instability of palindromic DNA in Escherichia coli. Cold Spring Harb Symp Quant Biol (1981) 2.75
Escherichia coli plasmids packageable in vitro in lambda bacteriophage particles. Methods Enzymol (1979) 2.71
Fertility and ageing. Hum Reprod Update (2005) 2.68
Changing character of cervical cancer in young women. BMJ (1989) 2.66
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol (2001) 2.59
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol (2011) 2.51
A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess (2005) 2.42
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
Sequence interruptions in enterobacterial repeated elements retain their ability to encode well-folded RNA secondary structures. Mol Microbiol (1997) 2.33
Free ribosomal DNA molecules from Tetrahymena pyriformis GL are giant palindromes. J Mol Biol (1976) 2.33
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
Precise and nearly-precise excision of the symmetrical inverted repeats of Tn5; common features of recA-independent deletion events in Escherichia coli. Gene (1983) 2.21
Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome. Am J Hum Genet (1995) 2.19
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med (2000) 2.17
Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer (1998) 2.12
Safer choices: reducing teen pregnancy, HIV, and STDs. Public Health Rep (2001) 2.07
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol (2001) 2.05